GSK Invests In Consumer Unit To Overcome Generic Threat, Low Alli Sales
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline expects to overcome increasing generic competition by growing its consumer health business and investing in emerging markets, rather than by pursuing a mega-merger like Pfizer-Wyeth
You may also be interested in...
Glaxo Consumer Finds Growth Groove Via Innovation, Acquisitions, Expansion
GlaxoSmithKline's consumer health care business appears back on track with 8 percent growth in the firm's latest earnings period, a year after it reported flat consumer sales hurt by the disappointing U.S. performance of weight-loss drug alli
Glaxo Consumer Finds Growth Groove Via Innovation, Acquisitions, Expansion
GlaxoSmithKline's consumer health care business appears back on track with 8 percent growth in the firm's latest earnings period, a year after it reported flat consumer sales hurt by the disappointing U.S. performance of weight-loss drug alli
Glaxo Consumer Finds Growth Groove Via Innovation, Acquisitions, Expansion
GlaxoSmithKline's consumer health care business appears back on track with 8 percent growth in the firm's latest earnings period, a year after it reported flat consumer sales hurt by the disappointing U.S. performance of weight-loss drug alli